Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial

Table 3 Adverse events and compliance

	mBCQT treatment (n = 68)	CT treatment (n = 68)	P value
Diarrhea	1.5 (1)	13.2 (9)	0.009
Feces discoloration	5.9 (4)	0 (0)	0.119
Nausea	16.2 (11)	16.2 (11)	0.999
Taste disturbance	5.9 (4)	14.7 (10)	0.090
Miscellaneous	22.1 (15)	20.6 (14)	0.834
Total adverse events	33.8 (23)	51.5 (35)	0.037
Compliance1	85.3 (58)	82.4 (56)	0.641

¹≥ 90% of medications taken. The values are percentages with numbers. mBCQT: Modified bismuth-containing quadruple therapy; CT: Concomitant therapy.